AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
阿斯利康的Sipavibart預防先兆性感染的營養素的申請被歐洲藥品管理局加速評估程序所接受，應用於免疫系統受損患者預防Covid-19。
AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
阿斯利康的Sipavibart預防先兆性感染的營養素的申請被歐洲藥品管理局加速評估程序所接受，應用於免疫系統受損患者預防Covid-19。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。